Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products
Merck has gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products.
Writing “How to Retire” helped Morningstar personal-finance expert Christine Benz learn a few surprising lessons.
Intel says a new $3 billion government deal reflects the “continued progress” of its foundry business.
The U.S. dollar has been sliding in the run-up to a widely expected interest-rate cut from the Federal Reserve on...
These retailers have been increasing same-store sales while improving their profit margins
Micron’s stock slumped Monday, just as a longer-term bearish chart pattern appeared for the first time in more than two...
Private equity isn’t all it’s cracked up to be, a review of Wall Street research shows